Weekly update Companies AI-cruiter Recruiting

Bolt Biotherapeutics

Founded: 2015

Location: Redwood City, CA

Employee range: 50 - 200

Clinical stage: Clin2

Therapy area: Breast cancer

Drug types: ONC

Lead product: BDC-1001

Product link: https://www.boltbio.com/pipeline-new/

Funding: $264M IPO Feb 2021; $93.5M C Jul 2020; $54M B Feb 2019

Investors: Pivotal bioVenture Partners, Nan Fung Life Sciences

boltbio.com

linkedin.com

job board

Short description:

Systemically delivered Immune-Stimulating Antibody Conjugates

Drug notes:

Also Clin1 multiple cancers; BDC-3042 Clin0 solid tumors; 4 undisclosed programs RD solid tumors, undisclosed

Long description:

Bolt Biotherapeutics is developing immuno-oncology therapies to eliminate tumors. Many tumors create an immune-suppressive environment to prevent their clearance. Bolt is leveraging the precision of antibody targeting to activate both the immune response in the tumor microenvironment. By identifying immune-stimulating antibody conjugates (ISACs), which Bolt refers to as Boltbody, a localized anti-tumor immune cascade can be stimulated to offer personalized therapeutic options. Using this approach, Bolt can address difficult-to-treat solid tumors and generate long-term anti-tumor responses through immunological memory. Bolt’s lead candidate, BDC-1001, is a HER2 BoltBody ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors.

Jobs:

Main

Contact: recruit@workinbiotech.com